share_log

TD Cowen Maintains Hold on Sage Therapeutics, Lowers Price Target to $9

Benzinga ·  Nov 22 00:51  · Ratings

TD Cowen analyst Ritu Baral maintains Sage Therapeutics (NASDAQ:SAGE) with a Hold and lowers the price target from $10 to $9.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment